slide 2 / 27 · slide 9 / 27 slide 10 / 27 page 5. undefined s5-02 neratinib after...

undefined

S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan

Slide 1 / 27

Slide 2 / 27

Page 1

undefined

S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan

Slide 3 / 27

Slide 4 / 27

Page 2

undefined

S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan

Slide 5 / 27

Slide 6 / 27

Page 3

undefined

S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan

Slide 7 / 27

Slide 8 / 27

Page 4

undefined

S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan

Slide 9 / 27

Slide 10 / 27

Page 5

undefined

S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan

Slide 11 / 27

Slide 12 / 27

Page 6

undefined

S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan

Slide 13 / 27

Slide 14 / 27

Page 7

undefined

S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan

Slide 15 / 27

Slide 16 / 27

Page 8

undefined

S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan

Slide 17 / 27

Slide 18 / 27

Page 9

undefined

S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan

Slide 19 / 27

Slide 20 / 27

Page 10

undefined

S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan

Slide 21 / 27

Slide 22 / 27

Page 11

undefined

S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan

Slide 23 / 27

Slide 24 / 27

Page 12

undefined

S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan

Slide 25 / 27

Slide 26 / 27

Page 13

undefined

S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan

Slide 27 / 27

Page 14